German pharmaceutical company Merck KGaA more than doubled its net profit in the fourth quarter, helped by higher prices for its Rebif multiple sclerosis drug and the company’s ongoing restructuring.

Net profit rose to 272 million euros ($355 million), from 133 million euros in the same quarter the year before. Revenues rose 8 per cent to 2.83 billion euros.

The Darmstadt-based company said today it was able to charge more for Rebif in the US, increasing sales 7.5 per cent to 1.89 billion euros. That offset slower sales growth for its Erbitux cancer drug.

Merck benefited from leaving profitable lines of business and regions in its consumer health division, which saw lower sales but higher profits as the company focused its efforts and investments on more lucrative products and regions. It outsourced the manufacturing and packaging of its Seven Seas brand cod liver oil products in Britain, for instance.

Earnings also received a boost from its business in liquid crystal materials used in flat panel displays. The performance materials division, where the liquid crystal business provides the bulk of sales, saw revenues grow 21 per cent in the fourth quarter. The division’s numbers were boosted 7 per cent for all of last year due to the dollar’s stronger exchange rate against the euro, which magnifies euro earnings figures. The division gets the bulk of its sales in dollars.

The company reported full-year profits decreased 7 per cent to 567 million euros as the company took 504 million euros in non-repeating restructuring charges. Revenues rose 9 per cent to 11.17 billion euros.

The company raised its dividend by 13 per cent to 1.70 euros per share.

Related Topics